Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
0.61% $16.40
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 861.35 mill |
EPS: | -1.620 |
P/E: | -10.12 |
Earnings Date: | May 01, 2024 |
SharesOutstanding: | 52.52 mill |
Avg Daily Volume: | 0.132 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -10.12 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.72x |
Company: PE -10.12 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$1.206 (-92.65%) $-15.19 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 15.37 - 17.43 ( +/- 6.29%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Fuhrman Alan | Buy | 932 | Common Stock |
2024-03-15 | Tada Hiroomi | Buy | 1 968 | Common Stock |
2024-03-15 | Harris Todd | Buy | 1 880 | Common Stock |
2024-03-11 | Bensen Daniel | Sell | 200 | Common Stock |
2024-03-06 | Bensen Daniel | Sell | 1 733 | Common Stock |
INSIDER POWER |
---|
85.11 |
Last 100 transactions |
Buy: 6 273 982 | Sell: 603 690 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $16.40 (0.61% ) |
Volume | 0.124 mill |
Avg. Vol. | 0.132 mill |
% of Avg. Vol | 93.91 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $18.30 | N/A | Active |
---|
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.